Mana Capital Acquisition Corp. Stock: price and management transactions · United States · SEC (Form 4)

About Mana Capital Acquisition Corp.

Mana Capital Acquisition Corp. is a U.S.-listed special purpose acquisition company (SPAC) rather than a traditional operating business. According to its SEC filings, the company was formed on May 19, 2021 in the State of Delaware as a blank check company for the purpose of completing a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more target businesses. Its principal executive offices were located at 8 The Green, Suite 12490, Dover, Delaware 19901. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1870144/000107997322000372/mana_10k-123121.htm)) For investors, the key point is that Mana Capital was designed as a capital markets vehicle, not as an operating industrial platform with recurring revenue streams. In its December 31, 2021 Form 10-K, the company explicitly identified itself as a shell company and disclosed Nasdaq-listed securities under the symbols MAAQ (common stock), MAAQU (units), MAAQW (warrants), and MAAQR (rights). That structure is typical for U.S. SPACs, where the investment case depends on sponsor quality, the ability to source an attractive target, and the execution of a value-accretive de-SPAC transaction. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1870144/000107997322000372/mana_10k-123121.htm)) From a history standpoint, Mana Capital was founded in 2021 and later entered into a business combination process with Cardio Diagnostics, Inc. SEC proxy and registration materials show that shareholders were asked to approve the merger in 2022, with the public company expected to be renamed Cardio Diagnostics Holdings Inc. after closing. This is important context for interpreting the company’s filings: the public shell’s life cycle was built around transaction completion, not organic scaling of products or services. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1870144/000107997322001301/mana_424b3.htm?utm_source=openai)) In competitive terms, Mana Capital operated in the highly crowded U.S. SPAC market, where differentiation is limited and mostly tied to sponsor credibility, capital structure, and the quality of the eventual acquisition target. The company did not have conventional business lines, manufacturing assets, or a product portfolio. Its core “business model” was to identify, negotiate, and complete a combination with a private company, creating a public listing path for the target. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1870144/000107997322000372/mana_10k-123121.htm)) Recent developments in the SEC record primarily relate to the transition from blank-check status into the Cardio Diagnostics combination, rather than ongoing operating news. For Form 4-focused investors, that means the most relevant signals are governance changes, post-merger ownership shifts, and capital-structure events rather than revenue or margin trends. In short, Mana Capital Acquisition Corp. is best understood as a U.S. Nasdaq-listed SPAC with an event-driven profile and a Delaware corporate base, rather than as a conventional operating company. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1870144/000107997322001301/mana_424b3.htm?utm_source=openai))